ARA-290 Nasal Spray
ARA-290 Nasal Spray contains ARA-290 (cibinetide), a synthetic 11-amino-acid peptide derived from the helix B region of erythropoietin (EPO) and investigated in experimental research, and is available from Direct SARMs in 15 ml and 30 ml sizes.
Sale!
99.3% purityBatch COA includedStore 2–8°C
Price range: $20.41 through $34.58
Buy more, save more
7.5% offspend $250.00
12.5% offspend $400.00
Spend $250.00 for 7.5% off on qualifying items · Applied automatically at checkout
Researchers who bought ARA-290 Nasal Spray also bought
ARA-290 Nasal Spray
ARA-290, also known as cibinetide or pyroglutamate helix B surface peptide (pHBSP), is a synthetic 11-residue peptide modelled on the three-dimensional structure of the helix B region of erythropoietin (EPO). Published scientific studies have investigated ARA-290 in experimental models involving EPO-derived signalling, the proposed EPOR/CD131 receptor complex, inflammatory pathways and cellular responses to tissue injury. Findings from these studies relate to the specific experimental models investigated and should not be interpreted as establishing effects associated with the nasal spray format.
Direct SARMs supplies ARA-290 as a pre-mixed aqueous nasal spray format for laboratory and analytical research. The 15 ml format contains 2 mg of ARA-290, while the 30 ml format contains 4 mg. The nasal spray designation describes the physical presentation of the material and does not establish intranasal bioavailability, biological activity, safety or suitability for administration.
Documentation includes a Certificate of Analysis (COA) and HPLC report. It is provided to support assessment of the stated product specifications, chromatographic purity and laboratory traceability.
ARA-290 Nasal Spray is supplied solely as a laboratory research material and is not intended for human or animal consumption or administration, or for diagnostic, therapeutic, clinical or veterinary use.
Benefits of the nasal spray format
1
The dispensing is pre-measured. Each time the spray mechanism is actuated, it releases a constant volume, which allows for repeatable dispensing when carrying out research procedures.
2
Convenient format. Compact spray bottles are straightforward to store, handle, and transport within an appropriate research environment.
3
Ready to use. Unlike lyophilized peptides, which are provided in vials, nasal spray formulations are in liquid form and do not need to be reconstituted before being handled in the laboratory.
4
Protected storage. The bottle protects the formulation by preventing unnecessary handling and exposure to the environment between research procedures.
5
Simple dispensing. The product can be dispensed easily. With an integrated spraying mechanism, it is not necessary to draw the liquid from a vial, offering a simple way to dispense the formulation during research.
Visit the ARA-290 Research Hub ▸
ARA-290 is supplied exclusively for laboratory research use. The information on this page is provided for scientific and educational reference and is based on available published research. This product is not intended for human or veterinary use, diagnosis, treatment, or prevention of any disease or medical condition. It is intended solely for qualified laboratory research and must be handled in accordance with applicable laboratory safety requirements.
Buy ARA-290 Nasal Spray Czech Republic from Direct SARMS.
Additional information
| Size(s) | 15ml and 30ml |
| Amount Per Nasal | 15ml = 2mg | 30ml = 4mg |
| Purity | 99.3% |
| Molecular Formula | C51H84N16O21 |
| Molecular Weight | 1257.31 g/mol |
| Sequence | XEQLERALNSS |
| Physical Form | Pre-mixed aqueous solution |
General information
Applies to all Direct Sarms research compounds unless noted otherwise on the product.
Storage & handling
Store the nasal spray according to the instructions provided on the product label. Keep the bottle securely closed when not in use and protect it from excessive heat and direct light. Follow any product-specific refrigeration requirements stated on the label.
Shipping & discretion
Fully tracked dispatch with worldwide shipping available. Sent in plain, discreet outer packaging with no product description on the label.
FDA disclosure & intended use
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease. Research use only — not for human or animal consumption. You must be 18+ and a qualified researcher.
Got a question about this ARA-290 compound?
ARA-290 Nasal Spray is supplied as a pre-mixed aqueous solution, providing the peptide in liquid form rather than as a dry or lyophilised research material.
Direct SARMs supplies ARA-290 Nasal Spray in 15 ml and 30 ml formats. The 15 ml format contains 2 mg of ARA-290, while the 30 ml format contains 4 mg.
The preparation contains ARA-290, also known as cibinetide or pyroglutamate helix B surface peptide (pHBSP). It is a synthetic 11-residue peptide modelled on the three-dimensional structure of the helix B region of erythropoietin (EPO).
The distinction relates primarily to the physical presentation of the research material. The nasal spray contains ARA-290 in a pre-mixed liquid solution, whereas lyophilised ARA-290 is supplied as a dry, freeze-dried material.
Documentation includes a Certificate of Analysis (COA) and HPLC report. HPLC data can provide information about chromatographic purity, while conclusions concerning molecular identity and other specifications should reflect the analytical methods documented for the individual batch.
Certificate of Analysis
| Identity | ARA-290 | CONFORMS |
| Purity (HPLC) | 99.3% | CONFORMS |
| Mass (LC-MS) | 1257.31 g/mol | CONFORMS |
| Appearance | Pre-mixed aqueous solution | CONFORMS |
